Vesicor Therapeutics IPO
Vesicor Therapeutics Holdings, Inc. · Danville, CA
IPO price
—
Listed
Mar 22, 2024
975 days ago
Raised
—
Registered maximum
Black Hawk is a blank-check company raising cash to merge with one private business in any industry or region.|Read more
Key takeaways
Summarised with AI from the 424B4 filed Mar 22, 2024. Check the prospectus before relying on it.
- 1Black Hawk raised $69.0 million by selling 6,900,000 units at $10.00, and $69,345,000 ($10.05 per public share) is placed in trust.
- 2Black Hawk has 15 months to close a merger, extendable twice by three months up to 21 months; each extension requires the sponsor to deposit $690,000 into the trust.
- 3The sponsor paid $25,000 for its founder shares, about $0.0145 per share, and will own about 21.96% of the shares after the offering.
- 4The auditor raised substantial doubt about Black Hawk's ability to continue as a going concern; it had $125,100 in cash and a $100,853 working capital deficit at November 30, 2023.
- 5Units carry rights rather than warrants: each right converts into one-fifth of a Class A share when a merger closes, and the rights expire worthless if no merger is completed.
Going-concern warning: may not have enough money to operate for the next year without new funding
Dual-class shares: some shares carry more votes than the ones sold in the IPO
Emerging growth company · Smaller reporting company
Offering terms
Units on the Nasdaq Global Market
- Shares offered
- 6.90M
- Over-allotment
- 1.03M
- Net proceeds (est.)
- $0
- Underwriting discount
- 4.5%
- Offering expenses
- $875K
- Lock-up
- 150 daysEnds ~Aug 19, 2024
- Who is locked up
- Sponsor and initial shareholders (founder shares); sponsor (private units); EF Hutton (representative shares). Founder shares are released at the earlier of six months after the merger or once Class A shares close at or above $12.00 on 20 of 30 trading days after the merger. Private units are locked until 30 days after the merger. Representative shares are locked until the later of the merger or 180 days.
- Dividends
- Black Hawk has not paid cash dividends and does not plan to pay any before completing its merger.
About Vesicor Therapeutics
Black Hawk Acquisition Corporation is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands on September 28, 2023. It has no operations or revenue. Its only purpose is to find and merge with one or more operating businesses.
Black Hawk sold 6,900,000 units at $10.00 each. Each unit holds one Class A share and one-fifth of a right. Each whole right converts into one Class A share when a merger closes. About $69.35 million ($10.05 per public share) goes into a U.S. trust account. Shareholders can redeem their shares for their portion of the trust if they don't want to take part in a deal.
Black Hawk has 15 months to complete a merger, which it can extend twice by three months each, up to 21 months. It does not limit its search to any industry or region. It says it is looking at targets with an enterprise value of about $180 million to $1 billion. The company is run by Kent Louis Kaufman, who is Chairman, CEO and CFO, and it has no specific target yet.
- Stage
- Blank-check company (SPAC)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Danville, CA
- CEO
- Kent Louis Kaufman
- Founded
- 2023
- Fiscal year end
- Nov 30
- SEC CIK
- 2000775
SPAC terms
A blank-check company raises cash first, then looks for a private company to merge with.
- Each unit
- One Class A ordinary share and one-fifth of one right
- In trust per unit
- $10.05
- Trust account
- $69.3M
- Time to find a deal
- 15 monthsOr the trust is returned
- Sponsor
- Black Hawk Management LLC
- Target focus
- Any industry or region; enterprise value of about $180 million to $1 billion
- Sponsor stake
- Approximately 20% of outstanding shares after the offering (excluding representative shares and private placement shares)
Strategy
Black Hawk has no business of its own and earns no revenue. It plans to use the trust money to merge with an operating company, and until then its only income is interest on the trust.
Market opportunity
Black Hawk does not limit its search to any industry or region. It plans to look for targets with an enterprise value of about $180 million to $1 billion in large markets with room to grow.
Strengths, as the company sees them
- Management network across several industries and global markets
- Experience structuring and executing deals
- Experience with cross-border transactions
Strategy
- Target companies with an enterprise value of about $180 million to $1 billion
- Look for strong, experienced management teams
- Favor targets with defensible market positions, IP, technology or brand
- No restriction on target geography
- Acquire businesses that would benefit from a U.S. public listing
Financials (USD)
Black Hawk is a new shell company with no revenue, $125,100 in cash, a $250,000 sponsor loan and going-concern doubt before the IPO.
Balance sheet, Nov 30, 2023
- Cash & investments
- $125K
- Debt
- $250K
- Stockholders' equity
- $6K
Key metrics
- Amount placed in trust
- $69,345,000At IPO closing
- Trust value per public share
- $10.05At IPO closing
- Working capital deficit
- $100,853As of November 30, 2023
- Expected annual trust interest (at 4.50%)
- $3,120,525Post-IPO estimate
- Cash held outside trust
- $445,000At IPO closing
Use of proceeds
Nearly all of the money, $69,345,000, goes into a trust account to fund a merger or repay shareholders who redeem. Black Hawk keeps $445,000 outside the trust to pay for its search for a target.
- Net proceeds to the company
- $69.8MAt $10.00 per unit, no over-allotment
- Cash expected to last
- At least 15 monthsWith existing cash
- 1Deposited in trust account for the business combination or shareholder redemptions$69.3M
- 2Legal, accounting and third-party expenses for target search, due diligence and deal negotiation$140K
- 3Legal and accounting fees for SEC reporting$50K
- 4Due diligence and research on prospective targets, including management expense reimbursement$50K
- 5Administrative fee to the sponsor ($10,000 per month for 15 months)$150K
- 6Working capital and reserves$55K
Ownership & dilution
- Shares before IPO
- 1.98M
- Shares after IPO
- 8.92M
- Insiders own after IPO
- 22%
- Dilution to new buyers
- $8.93/share107% of the price
- Book value per share after
- $-0.60vs $8.33 paid
- Selling stockholders
- None
Class B founder shares convert one-for-one into Class A shares when a merger closes, and 258,750 Class B shares are forfeited if the over-allotment option is not exercised.
| Principal holders | Before | After |
|---|---|---|
| Black Hawk Management LLC (Sponsor) · Sponsor | 100% | 22% |
| Kent Louis Kaufman · Insider | 100% | 22% |
Management & board
| Name | Background |
|---|---|
| Executive officers | |
| Kent Louis Kaufman, 66Chairman, Chief Executive Officer, Chief Financial Officer and Director | CEO of Growth and Leadership Center since 2004; managing partner at BEEC Capital; consultant for Korn Ferry; earlier at StorMedia and IBM |
| Board of directors | |
| Brandon Miller, 61Independent Director Nominee | Managing partner of Aspect Property Management; director of Yotta and Quetta Acquisition Corporations |
| Daniel M. McCabe, 74Independent Director Nominee | Runs Daniel McCabe LLC law practice; director of Yotta and Quetta Acquisition Corporations |
| Terry W. Protto, 75Independent Director Nominee | Former Macy's Vice Chairman-Operations and Finance; former CEO/President of Alpine 4 Holdings |
Funding before the IPO
Private rounds and loans disclosed in the registration statement.
| Date | Round | Amount | Price/share |
|---|---|---|---|
| Oct 16, 2023 | Founder sharesBlack Hawk Management LLC | $25K | $0.0145 |
| Oct 16, 2023 | Sponsor promissory noteBlack Hawk Management LLC | $250K | — |
| Mar 2024 | Private placement unitsBlack Hawk Management LLC | $2.4M | $10 |
Key risks
The most important of the risk factors the company lists. The prospectus has the full list.
- 1No target and a fixed deadline
Black Hawk has no merger target and must close a deal within 15 months, or up to 21 months with paid extensions. If it fails, public shares are redeemed from the trust and the rights expire worthless.
- 2Going concern doubt
The auditor raised substantial doubt about Black Hawk's ability to continue as a going concern. At November 30, 2023, it had $125,100 in cash and a $100,853 working capital deficit.
- 3Heavy dilution
New investors face immediate dilution of $8.93 per share, or 107.2%, after counting the shares issued for the rights. Founder shares cost the sponsor about $0.0145 each.
- 4Conflicts of interest
Two independent directors also sit on the boards of Yotta and Quetta Acquisition Corporations and may have to offer deals to those companies first. Management does not work full-time on Black Hawk's affairs.
- 5Limited SPAC experience
Black Hawk's officers and directors have no prior experience completing a merger for a blank-check company.
- 6Limited voting rights for public holders
Before a merger, only Class B holders, which means the sponsor, can vote on appointing or removing directors. The sponsor has agreed to vote its shares in favor of the merger.
- 7Trust exposed to creditor claims
Creditors' claims on the trust account could take priority over public shareholders. That could reduce the amount paid out per share.
Underwriters & advisers
- Bookrunners
- EF Hutton LLC
- Co-managers
- B. Riley Securities, Inc., RF Lafferty & Co., Inc.
- Auditor
- MaloneBailey, LLP
- Company counsel
- Celine and Partners, P.L.L.C.; Ogier (Cayman Islands)
- Underwriters' counsel
- Robinson & Cole LLP
- Transfer agent
- Continental Stock Transfer & Trust Company, 1 State Street, New York, New York 10004
- Over-allotment window
- 45 days
Prospectus & SEC filings
The registration statement, its amendments and the final prospectus, straight from SEC EDGAR.
| Date | Form | Document | Open |
|---|---|---|---|
| Nov 20, 2026 | 25-NSE | 25-NSE | |
| Nov 20, 2026 | CERT | Exchange listing certification | |
| Nov 20, 2026 | 8-A12B | Exchange registration (8-A) | |
| Mar 22, 2024 | 424B4 | Final prospectus (424B4) | |
| Mar 21, 2024 | CERT | Exchange listing certification | |
| Mar 20, 2024 | EFFECT | SEC notice of effectiveness | |
| Mar 20, 2024 | 8-A12B | Exchange registration (8-A) | |
| Mar 8, 2024 | S-1/A | Amended registration (S-1/A) · 2 documents | |
| Feb 26, 2024 | S-1/A | Amended registration (S-1/A) · 5 documents | |
| Feb 5, 2024 | S-1 | Registration statement (S-1) · 22 documents | |
| Dec 21, 2023 | DRS | Confidential draft (DRS) · 2 documents |
Vesicor Therapeutics IPO: frequently asked questions
More IPOs
Upcoming and recently priced deals.
Source: Vesicor Therapeutics Holdings, Inc.'s filings on SEC EDGAR. Dates marked approximate are derived from filing dates. Summaries are AI-assisted; the prospectus is the authority. This page is for information only and is not investment advice.